News
CPL’36 Phase II clinical results to be presented at APA Annual Meeting
We’re excited to share that we’ll be presenting at the American Psychiatric Association (APA) Annual Meeting 2025, taking place May 17–21 in Los Angeles, California. Our team will showcase the Phase 2 clinical trial results of CPL’36, an innovative PDE10A inhibitor, in the treatment of acute exacerbations of schizophrenia. 📌 Poster session: May 18, 1:30–3:00Read more »
Current report 4/2025 – Phase II top – line results for CPL’ 36, a PDE10a inhibitor in the treatment of Dyskinesia in Parkinson’s disease
Legal basis Art. 17 section 1 MAR – confidential information. Report content: In reference to current report 17/2024 regarding positive results of the Phase II clinical trial on a drug based on CPL’36, an innovative PDE10A inhibitor, in the treatment of schizophrenia, in which the Company informed about the simultaneous ongoing Phase II clinical trialRead more »
Current report 17/2024 – Positive Phase II top – line results for CPL’ 36, a PDE10A inhibitor in the treatment of acute schizophrenia
In reference to current report No. 26/2020 of September 30, 2020 on obtaining consent to start a Phase II clinical trial on a drug based on CPL’36, an innovative PDE10A inhibitor in patients with psychotic exacerbation of schizophrenia, the Management Board of Celon Pharma S.A. (the “Company”) announces positive Phase II top-line results of CPL’36,Read more »
Current report 11/2024 – Results of phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)
In reference to current reports 36/2021 on the successful completion of phase I clinical trial and 47/2021 on submission of an application for consent to commence a phase II trial of an innovative JAK/ROCK inhibitor – CPL 409116 – in the treatment of Rheumatoid Arthritis (RA), the Company’s Management Board hereby informs that on JuneRead more »
Current report No. 7/2024 – Opinion of the Supervisory’s Board on the Management Board’s recommendation on the payment of the dividend
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Date: 24/05/2024, g.17:13 In relation to the current report no. 5/2024 of 23 May 2024 on Management Board’s recommendation on the payment of the dividend, the Management Board of Celon Pharma S.A. (“Company”) hereby informs that on 24 May 2024 theRead more »
Current report No. 6/2024 – Notice on the convening of the Ordinary General Meeting of Celon Pharma S.A. on June 21, 2024 with draft resolutions
The Management Board of Celon Pharma S.A. (“the Company”), acting pursuant to Article 395 § 1, Article 399 § 1, Article 402 (1) and Article 402 (2) of the Commercial Companies Code, hereby convenes the Ordinary General Meeting (“Ordinary General Meeting”) on June 21, 2024 to be held at 09:30 AM at the Company’s ResearchRead more »
Current report No. 5/2024 – The Management Board’s recommendation on the payment of the dividend
The Management Board of Celon Pharma S.A. (the “Company”) informs that on May 23, 2024 it adopted a resolution on a recommendation for the Ordinary General Meeting of the Company on the payment of the dividend. The Management Board recommends the Company to pay out the dividend in the amount of PLN 0.08 (eight groszy)Read more »
Current report No. 3/2024 – Informing about the medicinal product ZARIXA to the pharmaceutical market regulators
In reference to current report No. 24/2023, the Management Board of Celon Pharma S.A. (“Company”) of December 21, 2023 on the decision of the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (“President of the Office for Registration of Medicinal Product”) concerning the issuance of a marketing authorization forRead more »
Current report No. 2/2024 – Appointment of the President of the Management Board for another term
Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: The Management Board of Celon Pharma S.A. (“Company) hereby informs that on 24 January 2024, the Supervisory Board of the Company, acting pursuant to Article 368(4) of the Commercial Companies Code inRead more »